Latest Commercialisation News

Sparc Technologies reveals up to 60% corrosion reduction in graphene-enhanced water-based epoxy coatings, reinforcing its leadership in sustainable protective coatings innovation.

Holista Colltech has inked a binding supply and development agreement with US-based Regenerex Pharma to exclusively supply proprietary ovine collagen for advanced wound care products, targeting the lucrative US market initially with plans for global expansion.

Alligator Energy has secured final regulatory approval to begin its in-situ Field Recovery Trial at the Samphire Uranium Project, advancing the development of its recently upgraded Blackbush Deposit resource.

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

Carnegie Clean Energy reported a $2.33 million net loss for FY2025 but made significant strides in commercialising its wave energy technologies, supported by new loans and a US subsidiary launch.

Nanoveu, via its subsidiary EMASS, has expanded its U.S. sales network with key manufacturer representatives to fast-track adoption of its ECS-DoT ultra-low power Edge AI chip across critical OEM hubs.

New Frontier Minerals reports exceptional assay results from its Harts Range Project, revealing high concentrations of heavy rare earth elements and niobium, setting the stage for its maiden drilling campaign and potential commercialisation.

X2M Connect has successfully completed an oversubscribed capital raise, securing $5.4 million to strengthen its balance sheet and accelerate growth across Asia and the Middle East.

INOVIQ Limited reported a $6.9 million net loss for FY25 while making significant strides in its exosome-based cancer diagnostics and therapeutics pipeline, including a breakthrough ovarian cancer screening test and promising CAR-exosome therapy results.

Cynata Therapeutics has entered a five-year At-the-Market Subscription Agreement with Acuity Capital, enabling access to up to $7.5 million in standby equity capital with full discretion over timing and pricing.

EOS has reported a 126% increase in its contract backlog to $307 million in 1H 2025, driven by strong demand for its defence and space technologies despite a revenue decline. The company secured a landmark €71.4 million high energy laser weapon export contract and continues to strengthen its balance sheet.

Medical Developments International Ltd reported an 18% increase in revenue to $39.1 million for FY25, returning to profitability with a net profit after tax of $0.1 million. The company advanced its Penthrox market expansion through regulatory approvals and new partnerships.